Jessica Mann to leave Evolva and join Roche

Jessica Mann to leave Evolva and join Roche
Reinach, Switzerland, 18 June 2010 - Evolva Holding SA (SIX: EVE) today announced that Dr. Jessica Mann will resign as Chief Medical Officer of Evolva as of 31 July 2010 to take up a Senior Development position as Head of Translational Medicine at Hoffman La Roche.

Jessica Mann was clinical advisor of Evolva from February 2008 until October 2009 when she became Chief Medical Officer and she has been instrumental in the planning and implementation of Evolva's clinical activities during this period. As of 1 August 2010, Dr Mann will become a member of the Clinical Advisory Board of Evolva. At Roche, Dr Mann will lead the team in charge of early clinical development activities for the Metabolic DTA.

Dr Alexandra Sorensen will continue as overall responsible for the combined pre-clinical and clinical activities at Evolva. The company has initiated the recruitment of a new Chief Medical Officer.

Neil Goldsmith, CEO and Managing Director of Evolva Holding SA commented, " Evolva has benefitted greatly from Jessica's unique competence and experience in clinical development. While we regret not having Jessica as a full-time team member in future, we appreciate that she has accepted to join our Clinical Advisory Board. "

-- ends --

Contact Details
Neil Goldsmith, CEO
[email protected]
+ 41 61 485 2005

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.